Our Mission is to provide our customers with confidence in key decisions at critical stages of drug discovery. Our Vision is to become indispensable to our customers as a trusted partner and provider of high quality drug discovery contract research services and products. We are determined to always offer the most current, relevant, informative, and predictive models of human disease. We are proud to bring a great and versatile collection of reliable research tools to help new ideas grow and discoveries happen.
BioAspect offers preclinical research services – specializing in efficacy and proof-of-principle studies using cellular, transgenic Drosophila, and rodent models of human diseases – to identify health benefits of pharmaceutical, biotechnology, and nutraceutical products. Located right in the heart of the Toronto research district, BioAspect is your neighbourhood biotechnology company.
Established in 2010, BioAspect is the go-to biotech products and research company in the area. We develop and distribute over 500,000 reliable research tools including ELISA kits, recombinant and native proteins, antibodies, competent cells, and PCR products amongst others. For contract research services, we offer drosophila and mouse models of neurodegenerative diseases, ageing, longevity, addiction, obesity, diabetes, cancer, and natural health products, in addition to behavioural testing.
We offer cell-based in vitro models to use as the first step in biological evaluation of the effects of treatment. These tests are fast, cost-effective and designed for screening of large number of agents. They provide information about efficacy, toxicity, as well as an insight into the mechanism of action.
Our cell-based models use relevant cell types, expressing targeted pathways. Possible readouts include markers of cell metabolic activity and viability, apoptosis, oxidative stress, or other disease-specific endpoints. To gain insight into the mechanism of action, we offer gene and protein expression analysis. We employ qPCR and gene pathway finder arrays. For protein quantification by ELISA we can use any kit from our extensive catalog of more than 200, 000 products.
We offer ELISA-guaranteed mouse monoclonal antibody development (at least two positive clones). Our flexible package may include:
We generate polyclonal antibodies in specific pathogen-free New Zealand rabbits. Our packages are tailored to Customer needs and may include:
Assessment of the pharmacokinetic (PK) profile and oral bioavailability (for oral drugs) of lead compounds in the early stages of a drug discovery greatly reduces attrition in drug development. For CNS drugs, minimal acceptable brain exposure has to be achieved to make a lead a viable development candidate. Concurrent optimisation of PK, oral bioavailability, and pharmacological activity is the best strategy to shorten the lead optimisation process and reduce the risk of failure.
We carry out PK studies in rats and mice. We offer any combination of the following:
BioAspect has not received any reviews.
BioAspect has not received any endorsements.